Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 630 is a protein containing an N-terminal KRAB (Kruppel-associated box) domain and 13 C2H2-type zinc finger domains, encoded by the ZNF630 gene in humans. It is thought to act as a transcription factor, binding DNA in a sequence-specific manner and regulating RNA polymerase II-dependent gene transcription. ZNF630 localizes to chromosome X and shows alternatively spliced transcript variants. While little direct functional or clinical activity data is available, genetic studies have linked mutations or variants in ZNF630 to hereditary spastic paraplegia 51 and atrial septal defect 9. No drugs or established disease biomarkers target this protein at present. ZNF630 is part of the large KRAB-ZNF protein family, which generally functions to control gene expression in development and disease states, but specific roles for ZNF630 remain incompletely characterized[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 630 (ZNF630).